Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

The pharmacy briefing

News & insight.

Canadian pharmacy and therapeutics news: recalls, shortages, guideline updates and developments in practice.

192 results
Medication Safety

Okotoks Pharmacy Replaces Blame With Learning to Strengthen Patient Safety

An Alberta College of Pharmacy profile shows how licensee Yasmin Mohamed Essa built a just culture around incidents and close calls: protect the patient first, examine system causes, report promptly, and turn team discussion into practical workflow changes.

Sep 28, 2026 · 2 min read Read briefing
Okotoks main street; geographic file photo, not the featured pharmacy. Qyd, CC BY-SA 3.0; resized/WebP. Image source | Image source
Practice Guidance

World Pharmacists Day 2026 Calls for Empowered Pharmacists and Healthier Futures

FIP marked World Pharmacists Day on September 25 under the theme ‘Empowering pharmacists for healthier futures,’ calling for investment in skills, recognition and system support. For Canadian pharmacy teams, the message turns a celebration into a practical agenda for access, prevention, resilience and sustainable care.

Sep 28, 2026 · 2 min read Read briefing
Photo: World Sikh Organization of Canada/Pexels — illustrative Canadian pharmacist image. Source: Image source · Pexels licence: Image source
Medication Safety

Health Canada Recalls Apo-Semaglutide Lot 7000636A Over Incorrect Dose Display

Apotex is recalling one lot of its 4 mg Apo-Semaglutide pen because the device may display and deliver 0.25 mg or 0.5 mg instead of the intended 1 mg dose. The Type II recall affects retailers in seven provinces.

Sep 28, 2026 · 2 min read Read briefing
Photo: PerPlex via Wikimedia Commons — illustrative injection-pen image; not the recalled Apo-Semaglutide product. Source: Image source · Public domain.
Medication Safety

Health Canada Issues Type I Recall for Limited Units of Multiple Sanofi Insulin Pens and Cartridges

Health Canada has issued a national Type I recall for 1,043 units from specified lots of Admelog, Apidra, Lantus, Toujeo and Trurapi that may have frozen during shipping. Only certain units within the listed lots are affected, so pharmacies should use Sanofi’s shipment-level notification rather than treating every unit in a listed lot as recalled.

Sep 28, 2026 · 2 min read Read briefing
Sanofi offices in Massy, France, 2015; file photo, not a recalled product or production site. Lionel Allorge, CC BY-SA 3.0; resized/WebP. Image source | Image source
Medication Safety

Health Canada Posts Type II Recall of Two IMAAVY Lots Over Possible Glass Particles

Health Canada has posted a national Type II recall for two lots of IMAAVY solution because they may contain glass particles. Hospital and institutional pharmacy teams should identify and isolate affected stock promptly.

Sep 26, 2026 · 2 min read Read briefing
Photo: Jonathan Borba/Pexels — illustrative medical-vial image; not the affected IMAAVY product. Source: Image source · Pexels licence: Image source
Medication Safety

Alberta Naloxone Kit Claims Will Require a Personal Health Number Starting October 1

Alberta's Community Based Naloxone program will require a patient-specific personal health number for pharmacy claims beginning October 1, 2026. Pharmacy teams should update workflows for PHN collection, referrals and regulated-member oversight.

Sep 26, 2026 · 2 min read Read briefing
Photo: New Brunswick / Nouveau-Brunswick via Wikimedia Commons — naloxone kit distributed in New Brunswick. Source: Image source · CC0 1.0: Image source
Practice Guidance

Canada's Drug Agency Recommends Public Coverage for Alzheimer's Drug Donanemab

Canada's Drug Agency has issued a draft recommendation supporting public reimbursement of donanemab for early Alzheimer's disease, with conditions on age, genetic status and price -- but the Alzheimer Society of Canada warns reimbursement alone won't guarantee access without system investment in diagnostics and infusion capacity.

Sep 24, 2026 · 3 min read Read briefing
US National Institute on Aging / Alzheimer's Disease Education and Referral Center, via Wikimedia Commons (public domain) -- a PET scan of a brain with Alzheimer's disease; illustrative, not from a specific patient in this recommendation.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.